色素沈着障害治療市場（治療：外用薬、レーザー療法、ケミカルピーリング、マイクロダーマブレーション、光線療法、その他）世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年

色素沈着疾患治療市場 - レポートの範囲

世界の色素沈着障害治療市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の色素沈着障害治療の収益を提供します2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間の市場を分析します。このレポートは、2023年から2031年までの世界の色素沈着障害治療市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、色素沈着性障害治療市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界の色素沈着障害治療市場の競合情勢を詳しく掘り下げています。世界の色素沈着性障害治療市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の色素沈着性障害治療市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

• イントロダクション
• 概要
• 市場力学
• 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

• パイプライン分析
• 主要製品/ブランド分析
• 主な合併と買収
• COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：治療法別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：治療別、2017年～2031年
  • 外用薬
  • レーザー治療
  • ケミカルピーリング
  • マイクロダーマブレーション
  • 光線療法
  • その他
• 市場魅力度分析：治療法別

第7章 世界市場の分析と予測：疾患適応別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：疾患適応別、2017年～2031年
  • 色素沈着低下
    • 白斑
    • アルビノ
    • その他
  • 色素沈着過剰
    • 肝斑
    • 炎症後色素沈着過剰
    • 太陽黒子
    • その他
• 市場魅力分析：疾患適応別

第8章 世界市場の分析と予測：エンドユーザー別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：エンドユーザー別、2017年～2031年
  • 病院
  • エステティッククリニックと皮膚科センター
  • その他
• 市場魅力分析：エンドユーザー別

第9章 世界市場の分析と予測：地域別

• 主な調査結果
• 市場金額予測：地域別、2017年～2031年
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
• 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

• 市場プレーヤー- 競争マトリックス（企業の階層および規模別）
• 市場シェア分析：企業別（2022年）
• 企業プロファイル
  • Bayer AG
  • Galderma SA（Nestle Skin Health SA）
  • SkinCeuticals
  • Pierre Fabre
  • EpiPharm AG
  • RXi Pharmaceuticals Corporation
  • Obagi Cosmeceuticals LLC（Obagi Medical）
  • Vivier Pharma

List of Tables

• Table 01: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
• Table 02: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 03: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2031
• Table 04: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Region, 2017-2031
• Table 05: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country, 2017-2031
• Table 06: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
• Table 07: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 08: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2031
• Table 09: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 10: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
• Table 11: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 12: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2031
• Table 13: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 14: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
• Table 15: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 16: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2031
• Table 17: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 18: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
• Table 19: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 20: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2031
• Table 21: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 22: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
• Table 23: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017-2031
• Table 24: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

• Figure 01: Global Pigmentation Disorder Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
• Figure 02: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by Treatment, 2022
• Figure 03: Global Pigmentation Disorder Treatment Market Value Share, by Treatment, 2022
• Figure 04: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by Disease Indication, 2022
• Figure 05: Global Pigmentation Disorder Treatment Market Value Share, by Disease Indication, 2022
• Figure 06: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by End-user, 2022
• Figure 07: Global Pigmentation Disorder Treatment Market Value Share, by End-user, 2022
• Figure 08: Global Pigmentation Disorder Treatment Market Value Share, by Region, 2022
• Figure 09: Global Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast, 2017-2031
• Figure 10: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
• Figure 11: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031
• Figure 12: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 13: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
• Figure 14: Global Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
• Figure 15: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017-2031
• Figure 16: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Region, 2017 and 2031
• Figure 17: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Region, 2017-2031
• Figure 18: North America Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 19: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country, 2017-2031
• Figure 20: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Country, 2017 and 2031
• Figure 21: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
• Figure 22: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 23: North America Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
• Figure 24: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031
• Figure 25: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
• Figure 26:North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 27: Europe Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 28: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
• Figure 29: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
• Figure 30: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
• Figure 31: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 32: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
• Figure 33: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031
• Figure 34: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
• Figure 35: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017-2031
• Figure 36: Asia Pacific Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 37: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
• Figure 38: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
• Figure 39: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
• Figure 40: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 41: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
• Figure 42: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031
• Figure 43: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
• Figure 44: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017-2031
• Figure 45: Latin America Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 46: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
• Figure 47: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
• Figure 48: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
• Figure 49: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 50: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
• Figure 51: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031
• Figure 52: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
• Figure 53: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017-2031
• Figure 54: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
• Figure 55: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
• Figure 56: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
• Figure 57: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031
• Figure 58: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031
• Figure 59: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031
• Figure 60: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031
• Figure 61: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031
• Figure 62: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017-2031

Pigmentation Disorder Treatment Market - Scope of Report

TMR's report on the global pigmentation disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pigmentation disorder treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pigmentation disorder treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pigmentation disorder treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pigmentation disorder treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pigmentation disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pigmentation disorder treatment market.

The report delves into the competitive landscape of the global pigmentation disorder treatment market. Key players operating in the global pigmentation disorder treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pigmentation disorder treatment market profiled in this report.

Key Questions Answered in Global pigmentation disorder treatment Market Report:

• What is the sales/revenue generated by pigmentation disorder treatment across all regions during the forecast period?
• What are the opportunities in the global pigmentation disorder treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Pigmentation Disorder Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global pigmentation disorder treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pigmentation disorder treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pigmentation disorder treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pigmentation Disorder Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pigmentation Disorder Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Treatment

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Treatment, 2017-2031
  • 6.3.1. Topical Drugs
  • 6.3.2. Laser Therapy
  • 6.3.3. Chemical Peels
  • 6.3.4. Microdermabrasion
  • 6.3.5. Phototherapy
  • 6.3.6. Others
• 6.4. Market Attractiveness Analysis, by Treatment

7. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Disease Indication

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Disease Indication, 2017-2031
  • 7.3.1. Hypopigmentation
    • 7.3.1.1. Vitiligo
    • 7.3.1.2. Albinism
    • 7.3.1.3. Others
  • 7.3.2. Hyperpigmentation
    • 7.3.2.1. Melasma
    • 7.3.2.2. Post-inflammatory Hyperpigmentation
    • 7.3.2.3. Solar Lentigines
    • 7.3.2.4. Others
• 7.4. Market Attractiveness Analysis, by Disease Indication

8. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by End-user, 2017-2031
  • 8.3.1. Hospitals
  • 8.3.2. Aesthetic Clinics & Dermatology Centers
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by Disease Indication

9. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2017-2031
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Pigmentation Disorder Treatment Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Treatment, 2017-2031
  • 10.3.1. Topical Drugs
  • 10.3.2. Laser Therapy
  • 10.3.3. Chemical Peels
  • 10.3.4. Microdermabrasion
  • 10.3.5. Phototherapy
  • 10.3.6. Others
• 10.4. Market Value Forecast, by Disease Indication, 2017-2031
  • 10.4.1. Hypopigmentation
    • 10.4.1.1. Vitiligo
    • 10.4.1.2. Albinism
    • 10.4.1.3. Others
  • 10.4.2. Hyperpigmentation
• 10.5. Melasma
  • 10.5.1. Post-inflammatory Hyperpigmentation
  • 10.5.2. Solar Lentigines
  • 10.5.3. Others
• 10.6. Market Value Forecast, by End-user, 2017-2031
  • 10.6.1. Hospitals
  • 10.6.2. Aesthetic Clinics & Dermatology Centers
  • 10.6.3. Others
• 10.7. Market Value Forecast, by Country, 2017-2031
  • 10.7.1. U.S.
  • 10.7.2. Canada
• 10.8. Market Attractiveness Analysis
  • 10.8.1. By Treatment
  • 10.8.2. By Disease Indication
  • 10.8.3. By End-user
  • 10.8.4. By Country

11. Europe Pigmentation Disorder Treatment Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Treatment, 2017-2031
  • 11.3.1. Topical Drugs
  • 11.3.2. Laser Therapy
  • 11.3.3. Chemical Peels
  • 11.3.4. Microdermabrasion
  • 11.3.5. Phototherapy
  • 11.3.6. Others
• 11.4. Market Value Forecast, by Disease Indication, 2017-2031
  • 11.4.1. Hypopigmentation
    • 11.4.1.1. Vitiligo
    • 11.4.1.2. Albinism
    • 11.4.1.3. Others
  • 11.4.2. Hyperpigmentation
    • 11.4.2.1. Melasma
    • 11.4.2.2. Post-inflammatory Hyperpigmentation
    • 11.4.2.3. Solar Lentigines
    • 11.4.2.4. Others
• 11.5. Market Value Forecast, by End-user, 2017-2031
  • 11.5.1. Hospitals
  • 11.5.2. Aesthetic Clinics & Dermatology Centers
  • 11.5.3. Others
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Treatment
  • 11.7.2. By Disease Indication
  • 11.7.3. By End-user
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Pigmentation Disorder Treatment Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Treatment, 2017-2031
  • 12.3.1. Topical Drugs
  • 12.3.2. Laser Therapy
  • 12.3.3. Chemical Peels
  • 12.3.4. Microdermabrasion
  • 12.3.5. Phototherapy
  • 12.3.6. Others
• 12.4. Market Value Forecast, by Disease Indication, 2017-2031
  • 12.4.1. Hypopigmentation
    • 12.4.1.1. Vitiligo
    • 12.4.1.2. Albinism
    • 12.4.1.3. Others
  • 12.4.2. Hyperpigmentation
    • 12.4.2.1. Melasma
    • 12.4.2.2. Post-inflammatory Hyperpigmentation
    • 12.4.2.3. Solar Lentigines
    • 12.4.2.4. Others
• 12.5. Market Value Forecast, by End-user, 2017-2031
  • 12.5.1. Hospitals
  • 12.5.2. Aesthetic Clinics & Dermatology Centers
  • 12.5.3. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Treatment
  • 12.7.2. By Disease Indication
  • 12.7.3. By End-user
  • 12.7.4. By Country/Sub-region

13. Latin America Pigmentation Disorder Treatment Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Treatment, 2017-2031
  • 13.3.1. Topical Drugs
  • 13.3.2. Laser Therapy
  • 13.3.3. Chemical Peels
  • 13.3.4. Microdermabrasion
  • 13.3.5. Phototherapy
  • 13.3.6. Others
• 13.4. Market Value Forecast, by Disease Indication, 2017-2031
  • 13.4.1. Hypopigmentation
    • 13.4.1.1. Vitiligo
    • 13.4.1.2. Albinism
    • 13.4.1.3. Others
  • 13.4.2. Hyperpigmentation
    • 13.4.2.1. Melasma
    • 13.4.2.2. Post-inflammatory Hyperpigmentation
    • 13.4.2.3. Solar Lentigines
• 13.5. Others
• 13.6. Market Value Forecast, by End-user, 2017-2031
  • 13.6.1. Hospitals
  • 13.6.2. Aesthetic Clinics & Dermatology Centers
  • 13.6.3. Others
• 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.7.1. Brazil
  • 13.7.2. Mexico
  • 13.7.3. Rest of Latin America
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Treatment
  • 13.8.2. By Disease Indication
  • 13.8.3. By End-user
  • 13.8.4. By Country/Sub-region

14. Middle East & Africa Pigmentation Disorder Treatment Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Treatment, 2017-2031
  • 14.3.1. Topical Drugs
  • 14.3.2. Laser Therapy
  • 14.3.3. Chemical Peels
  • 14.3.4. Microdermabrasion
  • 14.3.5. Phototherapy
  • 14.3.6. Others
• 14.4. Market Value Forecast, by Disease Indication, 2017-2031
  • 14.4.1. Hypopigmentation
    • 14.4.1.1. Vitiligo
    • 14.4.1.2. Albinism
    • 14.4.1.3. Others
  • 14.4.2. Hyperpigmentation
    • 14.4.2.1. Melasma
    • 14.4.2.2. Post-inflammatory Hyperpigmentation
    • 14.4.2.3. Solar Lentigines
    • 14.4.2.4. Others
• 14.5. Market Value Forecast, by End-user, 2017-2031
  • 14.5.1. Hospitals
  • 14.5.2. Aesthetic Clinics & Dermatology Centers
  • 14.5.3. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Treatment
  • 14.7.2. By Disease Indication
  • 14.7.3. By End-user
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. Bayer AG
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Galderma S.A. (Nestle Skin Health S.A)
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. SkinCeuticals
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Pierre Fabre
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. EpiPharm AG
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. RXi Pharmaceuticals Corporation
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Obagi Cosmeceuticals LLC (Obagi Medical)
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Vivier Pharma
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview